ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) EVP Glenn Baity sold 37,500 shares of the stock in a transaction that occurred on Thursday, October 5th. The stock was sold at an average price of $40.91, for a total transaction of $1,534,125.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Glenn Baity also recently made the following trade(s):

  • On Wednesday, August 30th, Glenn Baity sold 26,507 shares of ACADIA Pharmaceuticals stock. The stock was sold at an average price of $34.87, for a total transaction of $924,299.09.
  • On Wednesday, August 9th, Glenn Baity sold 14,322 shares of ACADIA Pharmaceuticals stock. The shares were sold at an average price of $34.88, for a total transaction of $499,551.36.
  • On Thursday, July 20th, Glenn Baity sold 38,097 shares of ACADIA Pharmaceuticals stock. The shares were sold at an average price of $30.00, for a total transaction of $1,142,910.00.

Shares of ACADIA Pharmaceuticals Inc. (NASDAQ ACAD) opened at 38.54 on Monday. ACADIA Pharmaceuticals Inc. has a 12 month low of $20.68 and a 12 month high of $41.20. The firm has a 50-day moving average of $36.00 and a 200 day moving average of $31.68. The firm’s market cap is $4.72 billion.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.72) by $0.17. ACADIA Pharmaceuticals had a negative return on equity of 62.08% and a negative net margin of 485.14%. The business had revenue of $30.50 million for the quarter, compared to the consensus estimate of $20.02 million. During the same period last year, the business earned ($0.63) EPS. The firm’s revenue was up 30400.0% compared to the same quarter last year. On average, equities research analysts anticipate that ACADIA Pharmaceuticals Inc. will post ($2.53) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Insider Selling: ACADIA Pharmaceuticals Inc. (ACAD) EVP Sells $1,534,125.00 in Stock” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another site, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/10/09/insider-selling-acadia-pharmaceuticals-inc-acad-evp-sells-1534125-00-in-stock.html.

ACAD has been the subject of several recent research reports. BidaskClub raised shares of ACADIA Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, June 21st. Zacks Investment Research raised shares of ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating and set a $31.00 price objective for the company in a research report on Tuesday, July 11th. ValuEngine raised shares of ACADIA Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Needham & Company LLC reaffirmed a “buy” rating and issued a $49.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Sunday, September 17th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Thursday. Six analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $46.21.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Elliott Management Corp increased its position in ACADIA Pharmaceuticals by 61.7% in the 2nd quarter. Elliott Management Corp now owns 1,256,795 shares of the biopharmaceutical company’s stock worth $35,052,000 after buying an additional 479,413 shares during the period. York Capital Management Global Advisors LLC bought a new position in ACADIA Pharmaceuticals in the 2nd quarter worth approximately $3,347,000. State Street Corp increased its position in ACADIA Pharmaceuticals by 15.8% in the 2nd quarter. State Street Corp now owns 3,748,468 shares of the biopharmaceutical company’s stock worth $104,551,000 after buying an additional 510,670 shares during the period. Palo Alto Investors LLC increased its position in ACADIA Pharmaceuticals by 1.4% in the 2nd quarter. Palo Alto Investors LLC now owns 1,613,330 shares of the biopharmaceutical company’s stock worth $44,996,000 after buying an additional 22,900 shares during the period. Finally, Janus Henderson Group PLC bought a new position in ACADIA Pharmaceuticals in the 2nd quarter worth approximately $102,152,000. 97.10% of the stock is currently owned by institutional investors.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).

Insider Buying and Selling by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Stock Ratings for ACADIA Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.